Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of RO5212054 (PLX3603) in Participants With BRAF V600-Mutated Advanced Solid Tumors
- First Posted Date
- 2010-06-14
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 45
- Registration Number
- NCT01143753
- Locations
- 🇦🇺
Royal Adelaide Hospital; Oncology, Adelaide, South Australia, Australia
🇪🇸Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain
🇩🇰Rigshospitalet, Onkologisk Klinik, København Ø, Denmark
A Study of RO5045337 in Patients With Liposarcomas Prior to Debulking Surgery
- First Posted Date
- 2010-06-14
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT01143740
A Study of Bevacizumab Added to Trastuzumab Plus Docetaxel in the Neoadjuvant Setting in Participants With Early Stage HER2-Positive Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- Procedure: SurgeryRadiation: RadiotherapyDrug: Hormonal Therapy
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2018-03-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 152
- Registration Number
- NCT01142778
- Locations
- 🇫🇷
Centre Leon Berard; Oncologie Genetique, Lyon, France
🇫🇷Centre D'Oncologie de Gentilly; Oncology, Nancy, France
🇫🇷Centre Radiotherapie Marie Curie, Arras, France
A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2015-02-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 90
- Registration Number
- NCT01135498
Accu-Chek missiOn: SMBG in Patients With diAbetes on inSulin Study (COMPASS) - Multiple Center, Open, and Non-randomized Study
Not Applicable
Completed
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Device: Accu-Chek Integra Glucometer
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 833
- Registration Number
- NCT01130480
A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer
Phase 2
Completed
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2015-10-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 36
- Registration Number
- NCT01130337
A Study of Avastin (Bevacizumab) in Combination Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2015-06-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 306
- Registration Number
- NCT01131078
A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis
Completed
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- First Posted Date
- 2010-05-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6054
- Registration Number
- NCT01128257
SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNF Alfa Therapy
- First Posted Date
- 2010-05-19
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 224
- Registration Number
- NCT01126541
A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis
Phase 4
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2010-05-10
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 326
- Registration Number
- NCT01119859
© Copyright 2025. All Rights Reserved by MedPath